Combination Treatment with Cisplatin and Schizophyllan for 7,12‐dimethylbenz(a)anthracene‐Induced Rat Ovarian Adenocarcinoma

Sugiyama, Toru; Nishida, Takashi; Kumagai, Shogo; Imaishi, Kiyohisa; Ushijima, Kimio; Kataoka, Akio; Yakushiji, M

doi:10.1111/j.1447-0756.1995.tb01047.x

Cited by 5 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DMBA-induced ovarian carcinogenesis provides a wellcontrolled experimental model of ovarian cancer. 27,28 The development of ovarian cancer in such a model could resemble that developed in women, which was therefore can be introduced into our study on an interventional gene therapy for ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Enhanced efficiency and specificity of ovarian cancer gene therapy in rats with a novel nonviral gene delivery system (GE7) via intraovarian artery perfusion approach

et al. 2005

View full text Add to dashboard Cite

Transfer of the herpes simplex virus type I-thymidine kinase gene, followed by the administration of ganciclovir (HSV 1 -tk/GCV) into ovarian cancer-derived cell line either in vitro or transplanted into nude mice has been shown to provide a potential strategy for the gene therapy of ovarian cancer. We investigated the antitumor effects of HSV 1 -tk/GCV strategy with a chemically induced rat ovarian cancer model and a tumor-selective gene delivery by a novel nonviral gene delivery system (GE7) through the ovarian artery and tail vein. We demonstrated the expression of a reporter gene, b-gal gene, as well as HSV 1 -tk gene in tumors and other organs, evaluated the overall antitumor effects after the GCV treatment and analyzed the tumor cell cycle phase distribution. Via the ovarian artery route, the expressions of b-gal and HSV 1 -tk in tumors were significantly stronger than those expressed in such organs as the hearts, livers, spleens, lungs and kidneys. However, no b-gal and HSV 1 -tk were detected in the tumor tissues when administrated via the tail vein, and little was found in other organs. The cell cycle analysis showed that the total S-phase of tumor cells in the test intra-arterial treatment group was considerably higher than that of the controls. The weight of the tumor tissues in the group treated by the intra-arterial route (4.0672.12 g) was much less than the group treated intravenously (18.2578.34 g) (Po.01). These findings indicated that the administration of GE7/HSV 1 -tk complex via the ovarian artery route could be a promising avenue of future human ovarian cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%